PureTech Presents Phase 1b Results for LYT-200 in High-Risk Myelodyspastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026. Company announcement - FT.com.

Financial Times Markets · Source